



Development and Validation of a Bioanalytical Method for determination of Teneigliptin in Human Plasma by RP-HPLC

Vaishali D Dandge^{1*}, Vaishnavi Malve¹, V M Waghulkar¹,
A W Baitule¹, S G Jawarkar¹

¹Vidyabharti College of Pharmacy, C.K. Naidu road, Amravati, Maharashtra,
India 444602

Corresponding E-mail id: vaishalidd15@gmail.com

Abstract: A simple, reliable, precise, accurate, sensitive and selective RP-HPLC method was developed and validated for estimation of Teneigliptin in Human plasma using protein precipitation extraction method. Teneigliptin is an antidiabetic drug from the class called Dipeptidyl peptidase-4 (DPP-4) inhibitor. The chromatographic separation was carry out using AGILENT C18 column (250mm x 4.6ID) as stationary phase and mobile phase of Methanol and 0.05% orthophosphoric acid solution in ratio of 70:30 v/v with pH of 2.7 at flow rate of 0.7 ml/min. Detection was carry out at 245nm using DAD detector. The injection volume was 20 μ l. The run time was 8min. The retention time of Teneigliptin was shorter i.e. 3.5 min. The overall recovery of teneigliptin was 97.83%. The calibration curve was linear over the concentration range of 5-25 μ g /ml. Accuracy ranges from 98.82% to103.28 % with the precision 1.41% to 3.06% in intra-day method. In inter-day method the accuracy ranges from 99.80% to 103.33% with the precision 2.12% to 5.29%. The Lower limit of quantification (LLOQ) and the Limit of Detection (LOD) for Teneigliptin were found to be 2.09 μ g/ml and 0.69 μ g/ml respectively. The method developed can be used in therapeutic drug monitoring units, bioequivalence and bioavailability studies, pharmacokinetic and toxicology studies of Teneigliptin.

Keywords : Teneigliptin, Bioanalytical method, Bioanalytical validation, RP-HPLC, Human Plasma.

Vaishali D Dandge *et al*/International Journal of PharmTech Research, 2022,15(2):48-57.

DOI: <http://dx.doi.org/10.20902/IJPTR.2022.150204>
